Search results for "REDUCTASE"

showing 10 items of 798 documents

Fixation conditions affect the intensity but not the pattern of NADPH-diaphorase staining as a marker for neuronal nitric oxide synthase in rat olfac…

1994

NADPH-diaphorase (NADPH-d) is commonly used as a histochemical marker for the neuronal form of the enzyme nitric oxide synthase (NOS). A recent biochemical study showed that in broken-cell preparations NADPH-d activity did not fully represent NOS and that NOS-unrelated NADPH-d activity was suppressed during fixation. Because it is unknown whether fixation also affects NOS-associated NADPH-d activity, we investigated the effects of various widely used fixatives on NADPH-d staining in relation to NOS immunoreactivity, obtained with polyclonal antibodies, in rat olfactory bulb. We found that the intensity of NADPH-d staining associated with NOS, as well as that unrelated to NOS, depends on fi…

MalePathologymedicine.medical_specialtyTissue FixationHistologyLysineSensitivity and SpecificityStainImmunoenzyme TechniquesRats Sprague-DawleymedicineAnimalsFixativeNeuronschemistry.chemical_classificationStaining and LabelingbiologyChemistryNADPH DehydrogenaseOlfactory BulbMolecular biologyRatsOlfactory bulbStainingNitric oxide synthaseEnzymePolyclonal antibodiesbiology.proteinAmino Acid OxidoreductasesNitric Oxide SynthaseAnatomyBiomarkersJournal of Histochemistry & Cytochemistry
researchProduct

Cocaine hepatotoxicity: two different toxicity mechanisms for phenobarbital-induced and non-induced rat hepatocytes.

1993

Abstract Hepatocytes isolated from both phenobarbital-induced and control rats were short-term cultured and exposed to cocaine (8–2000 μM) for varying times. Intracellular lactate dehydrogenase activity, free calcium levels ([Ca 2+ ] i ), reduced glutathione (GSH) and lipid peroxidation were investigated to evaluate the toxic effect of cocaine on hepatocytes. Cytochrome P450 induction by phenobarbital potentiated the in vitro cytotoxicity of cocaine by a factor of 13 (IC 50 = 84 μ M induced cells vs 1100 μM in non-induced cells). This difference in the susceptibility of the two types of hepatocytes to cocaine correlated well with the activity of cytochrome P450 2 B 1 2 . Rapid depletion of …

MaleProgrammed cell deathCell SurvivalPharmacologyBiochemistryLipid peroxidationRats Sprague-Dawleychemistry.chemical_compoundCocaineCytochrome P-450 Enzyme SystemLactate dehydrogenasemedicineAnimalsCells CulturedPharmacologybiologyDose-Response Relationship DrugCytochrome P450GlutathioneGlutathioneRatschemistryLiverPhenobarbitalToxicityCytochrome P-450 CYP2B1biology.proteinPhenobarbitalCalciumLipid PeroxidationOxidoreductasesIntracellularmedicine.drugBiochemical pharmacology
researchProduct

Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis

2013

[Background]: Pulmonary hypertension in idiopathic pulmonary fibrosis (IPF) is indicative of a poor prognosis. Recent evidence suggests that tetrahydrobiopterin (BH4), the cofactor of nitric oxide synthase (NOS), is involved in pulmonary hypertension and that pulmonary artery endothelial-to-mesenchymal transition (EnMT) may contribute to pulmonary fibrosis. However, the role of BH4 in pulmonary remodelling secondary to pulmonary fibrosis is unknown. This study examined the BH4 system in plasma and pulmonary arteries from patients with IPF as well as the antiremodelling and antifibrotic effects of the BH4 precursor sepiapterin in rat bleomycin-induced pulmonary fibrosis and in vitro EnMT mod…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtySepiapterinPathologyNitric Oxide Synthase Type IIIHypertension PulmonaryPulmonary FibrosisNitric Oxide Synthase Type IIEnzyme-Linked Immunosorbent AssayPulmonary ArteryReal-Time Polymerase Chain ReactionEndothelial NOSchemistry.chemical_compoundIdiopathic pulmonary fibrosisInternal medicinemedicine.arteryPulmonary fibrosismedicineAnimalsHumansRats WistarGTP CyclohydrolaseSepiapterin reductaseChromatography High Pressure LiquidAgedbusiness.industryNitrotyrosineMiddle Agedmedicine.diseaseBiopterinImmunohistochemistryPulmonary hypertensionRatsAlcohol OxidoreductasesDisease Models AnimalEndocrinologychemistryPulmonary arteryTyrosineFemaleEndothelium Vascularbusiness
researchProduct

Statins, Fracture Risk, and Bone Remodeling: What Is True?

2006

Besides the action on plasma lipid levels, statins show a series of ancillary effects defined as all of their vascular and nonvascular effects independent from the cholesterol reduction. It has been recently hypothesized that one of these ancillary effects could be the improvement of bone health, due to the interference with bone metabolism. This may potentially represent the rationale for statins' use in the treatment of osteoporosis, the most common disease of the bone. Both experimental observations and clinical studies on this topic generated a number of conflicting results; however, the largest randomized clinical trials, the Scandinavian Simvastatin Survival Study (4S), Long Term Inte…

MaleRiskSimvastatinmedicine.medical_specialtyOsteoporosisMyocardial IschemiaBioinformaticsBone remodelinglaw.inventionFractures Bonechemistry.chemical_compoundRandomized controlled trialRisk FactorslawHumansMedicineLongitudinal StudiesRisk factorPravastatinRandomized Controlled Trials as Topicbusiness.industryCholesterolOsteoporosiStatinnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseSurgerychemistrySimvastatinOsteoporosisFemalelipids (amino acids peptides and proteins)Bone RemodelingTherapyHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessFracturesHeart Protection StudyPravastatinmedicine.drugThe American Journal of the Medical Sciences
researchProduct

The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndro…

2010

The R3i Foundation (Residual Risk Reduction Initiative), an independent, multinational and academic organization, is conducting the REALIST (Residual Risk, Lipids and Standard Therapies) study in 40 centers in different countries. This is a retrospective epidemiological study, designed to provide new data on the residual risk of major coronary events attributable to lipid abnormalities in patients receiving the current standard treatment. The initial results are expected in mid 2010, and the overall results at the end of 2010.

MaleRiskmedicine.medical_specialtyAcute coronary syndromeInternational CooperationRisk AssessmentMedical RecordsMeta-Analysis as TopicRecurrenceInternal medicinemedicineHumansAcute Coronary SyndromeAgedDyslipidemiasRetrospective StudiesAged 80 and overHypertriglyceridemiamedicine.diagnostic_testbusiness.industryPatient SelectionStandard treatmentCholesterol HDLCase-control studyRetrospective cohort studyCholesterol LDLMiddle AgedAtherosclerosismedicine.diseaseLipidsSurgeryResidual riskCardiovascular DiseasesCase-Control StudiesFemaleHydroxymethylglutaryl-CoA Reductase InhibitorsLipid profileRisk assessmentbusinessDyslipidemiaEndocrinología y Nutrición (English Edition)
researchProduct

Anti-inflammatory and joint protective effects of extra-virgin olive-oil polyphenol extract in experimental arthritis

2014

The consumption of extra virgin olive oil (EVOO) in Mediterranean countries has shown beneficial effects. A wide range of evidence indicates that phenolic compounds present in EVOO are endowed with anti-inflammatory properties. In this work, we evaluated the effects of EVOO-polyphenol extract (PE) in a model of rheumatoid arthritis, the collagen-induced arthritis model in mice. On day 0, DBA-1/J mice were immunized with bovine type II collagen. On day 21, mice received a booster injection. PE (100 and 200 mg/kg) was orally administered once a day from days 29 to 41 to arthritic mice. We have demonstrated that PE decreases joint edema, cell migration, cartilage degradation and bone erosion. …

MaleSTAT3 Transcription Factormedicine.drug_classEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryAnti-Inflammatory AgentsType II collagenAdministration OralDown-RegulationArthritisPharmacologyp38 Mitogen-Activated Protein KinasesBiochemistryDinoprostoneAnti-inflammatoryProinflammatory cytokineMiceEdemamedicineAnimalsPlant OilsPhosphorylationProstaglandin E2Olive OilMolecular BiologyProstaglandin-E SynthasesActivating Transcription Factor 3Nutrition and DieteticsChemistryJNK Mitogen-Activated Protein KinasesNF-kappa BPolyphenolsmedicine.diseaseArthritis ExperimentalIntramolecular OxidoreductasesCyclooxygenase 2Mice Inbred DBARheumatoid arthritisImmunologyCytokinesmedicine.symptomSignal TransductionProstaglandin Emedicine.drugThe Journal of Nutritional Biochemistry
researchProduct

Species differences in activating and inactivating enzymes related to the control of mutagenic metabolites

1977

Microsomal monooxygenases catalyze the biosynthesis of epoxides from olefinic and aromatic compounds whilst microsomal epoxide hydratase and cytoplasmic glutathione S-transferases are responsible for their further biotransformation. Although catalytically very efficient the cytoplasmic glutathione S-transferases play, due to their subcellular localization, a minor role in the inactivation of epoxides derived from large lipophilic compounds and were, therefore, not included in this study. It was shown with such a lipophilic compound, benzo(a)pyrene, as a model substance and with liver enzyme mediated bacterial mutagenesis as biological endpoint that species and strain differences in epoxide …

MaleSalmonella typhimuriumHealth Toxicology and MutagenesisToxicologyMixed Function OxygenasesMicechemistry.chemical_compoundSpecies SpecificityBiotransformationBiosynthesisCoumarinsAnimalsBenzopyrenesBiotransformationEpoxide Hydrolaseschemistry.chemical_classificationMutagenesisGeneral MedicineGlutathioneMonooxygenaseRatsEnzymeBenzo(a)pyrenechemistryBiochemistryPhenobarbitalMicrosomes LiverMicrosomeFemaleOxidoreductasesMethylcholanthreneMutagensArchives of Toxicology
researchProduct

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

2021

Background The European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry provides a platform for the global surveillance of familial hypercholesterolaemia through harmonisation and pooling of multinational data. In this study, we aimed to characterise the adult population with heterozygous familial hypercholesterolaemia and described how it is detected and managed globally. Methods Using FHSC global registry data, we did a cross-sectional assessment of adults (aged 18 years or older) with a clinical or genetic diagnosis of probable or definite heterozygous familial hypercholesterolaemia at the time they were entered into the registries. Dat…

MaleSettore MED/09 - Medicina InternaArterial diseaseCross-sectional studyAdult populationCoronary DiseaseDiseaseGlobal HealthMedical and Health SciencesDoenças Cardio e Cérebro-vascularesAnticholesteremic AgentMonoclonalPrevalenceRegistriesFamilial HypercholesterolemiaHumanizedStroke11 Medical and Health SciencesLS2_9Studies CollaborationAnticholesteremic AgentsGeneral MedicineHeart Disease Risk FactorMiddle AgedFHSC global registry dataEuropeTreatment OutcomeLower prevalenceGuidancelipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Familial hypercholesterolaemiaLife Sciences & BiomedicineHumanAdultmedicine.medical_specialtyCombination therapyFHSC global registry heterozygous familial hypercholesterolaemiaCardiovascular risk factorsAntibodies Monoclonal HumanizedInsightsAntibodiesNOHyperlipoproteinemia Type IIClinicianMedicine General & InternalInternal medicineGeneral & Internal MedicineHealth SciencesmedicineHumansEAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)Cross-Sectional StudieScience & TechnologyGlobal Perspectivebusiness.industryCholesterol LDLmedicine.diseaseCross-Sectional StudiesHeart Disease Risk FactorsHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness
researchProduct

Under-prescription of statins in patients with non-alcoholic fatty liver disease

2017

Abstract Background and Aim Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with high cardiovascular risk. Management of dyslipidaemia plays a pivotal role in the prevention of CV events and statins have proved to be safe in these patients. However, in everyday clinical practice statin prescription is sometimes limited because of the concern of physicians about side-effects. The aim of the study was to investigate if the presence of NAFLD affects the prescription of lipid-lowering treatment in a large series of patients with cardio-metabolic disorders. Methods and Results Cardiovascular risk and LDL-C targets were defined according to ESC/EAS Guidelines in 605 conse…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Disease030204 cardiovascular system & hematologyEndocrinology0302 clinical medicineDrug PrescriptionNon-alcoholic Fatty Liver DiseaseRisk FactorsCardiovascular DiseaseNutrition and DieteticPractice Patterns Physicians'Nutrition and Dieteticsmedicine.diagnostic_testFatty liverMiddle AgedDiabetes and MetabolismCardiovascular DiseasesPractice Guidelines as TopicCohortUnder-prescriptionFemalelipids (amino acids peptides and proteins)030211 gastroenterology & hepatologyGuideline AdherenceCardiology and Cardiovascular MedicineHumanAdultCardiovascular risk; Non-alcoholic fatty liver disease; Statins; Under-prescription; Medicine (miscellaneous); Endocrinology Diabetes and Metabolism; Nutrition and Dietetics; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyStatinmedicine.drug_classContext (language use)Health Services MisuseDrug Prescriptions03 medical and health sciencesInternal medicinemedicineHumansMedical prescriptionAgedDyslipidemiasCross-Sectional Studiebusiness.industryRisk FactorStatinsStatinnutritional and metabolic diseasesNon alcoholicBiomarkerCholesterol LDLCardiovascular riskmedicine.diseaseCross-Sectional StudiesDyslipidemiaPhysical therapyHydroxymethylglutaryl-CoA Reductase InhibitorHydroxymethylglutaryl-CoA Reductase InhibitorsLipid profilebusinessBiomarkersNutrition, Metabolism and Cardiovascular Diseases
researchProduct

The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice

2014

Reducing low-density lipoprotein cholesterol (LDL-C) levels using statins is associated with significant reductions in cardiovascular (CV) events in a wide range of patient populations. Although statins are generally considered to be safe, recent studies suggest they are associated with an increased risk of developing Type 2 diabetes (T2D). This led the US Food and Drug Administration (FDA) to change their labelling requirements for statins to include a warning about the possibility of increased blood sugar and HbA1c levels and the European Medicines Agency (EMA) to issue guidance on a small increased risk of T2D with the statin class. This review examines the evidence leading to these clai…

MaleSettore MED/09 - Medicina Internaendocrine system diseasesHSM MEDHydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effectsAnticholesteremic Agents/adverse effectsMedizin1567-5688ComorbidityType 2 diabetesPharmacologyDiabeteHydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosageCardiovascularFasting/bloodCohort StudiesRisk FactorsAnticholesteremic Agents/administration & dosageDiabetes Mellitus Type 2/prevention & controlMulticenter Studies as TopicMedicineT2DDiabetisAnticholesteremic AgentsDiabetesHemoglobin A Glycosylated/analysisFastingGeneral MedicineMiddle AgedDiabetogenicityCVDClinical PracticeObservational Studies as TopicCholesterol LDL/bloodCardiovascular DiseasesPractice Guidelines as Topiclipids (amino acids peptides and proteins)Disease SusceptibilityCardiology and Cardiovascular MedicineRisk assessmentCardiovascular Diseases/prevention & controlCohort studyAdultmedicine.medical_specialtyStatinHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic usemedicine.drug_classAnticholesteremic Agents/therapeutic useHydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacologyDiabetes Mellitus Type 2/etiologyRisk AssessmentMulticenter Studies as Topic/statistics & numerical dataPrediabetic StateMeta-Analysis as TopicDiabetes mellitusInternal MedicineHumansIntensive care medicinePrediabetic State/epidemiologyGlycated HemoglobinStatins; Diabetes; Diabetogenicity; T2D; Cardiovascular; CVDbusiness.industryCardiovascular Diseases/epidemiologyStatinsStatinnutritional and metabolic diseasesCholesterol LDLmedicine.diseaseComorbidityAnticholesteremic Agents/pharmacologyDiabetes Mellitus Type 2/epidemiologyDiabetes Mellitus Type 2Estatines (Medicaments cardiovasculars)Observational Studies as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessObservational Study as TopicForecasting
researchProduct